APO Research
Talk to an analyst

APO RESEARCH · REPORT

Immune Thrombocytopenia Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Immune Thrombocytopenia Drugs Market Analysis and Forecast 2026-2032

22 December 2025198 pages

Choose your research edition.

Industry ResearchImmune Thrombocytopenia Drugs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Immune Thrombocytopenia Drugs Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Immune Thrombocytopenia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immune Thrombocytopenia Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Immune Thrombocytopenia Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Immune Thrombocytopenia Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Immune Thrombocytopenia Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Immune Thrombocytopenia Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Immune Thrombocytopenia Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Immune Thrombocytopenia Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Immune Thrombocytopenia Drugs include Novartis AG, Merck & Co., Inc., Amgen Inc., Rigel Pharmaceuticals Inc., Horizon Therapeutics Plc and CSL Ltd., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Immune Thrombocytopenia Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Immune Thrombocytopenia Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Immune Thrombocytopenia Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Immune Thrombocytopenia Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Immune Thrombocytopenia Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Immune Thrombocytopenia Drugs revenue, projected growth trends, production technology, application and end-user industry.

Immune Thrombocytopenia Drugs Segment by Company

Novartis AG

Merck & Co., Inc.

Amgen Inc.

Rigel Pharmaceuticals Inc.

Horizon Therapeutics Plc

CSL Ltd.

Immune Thrombocytopenia Drugs Segment by Type

Intravenous Immunoglobins (IVIGs)

Corticosteroids

Thrombopoietin Receptor Agonists (TPO-RAs)

Other Drugs

Immune Thrombocytopenia Drugs Segment by Application

Hospitals and Diagnostic Centers

Academic Institutes and Research Organizations

Biotechnology and Pharmaceutical Companies

Immune Thrombocytopenia Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immune Thrombocytopenia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immune Thrombocytopenia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immune Thrombocytopenia Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Immune Thrombocytopenia Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Immune Thrombocytopenia Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Immune Thrombocytopenia Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Immune Thrombocytopenia Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Intravenous Immunoglobins (IVIGs) Major Player Table 3. Corticosteroids Major Player Table 4. Thrombopoietin Receptor Agonists (TPO-RAs) Major Player Table 5. Other Drugs Major Player Table 6. Global Immune Thrombocytopenia Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospitals and Diagnostic Centers Major Player Table 8. Academic Institutes and Research Organizations Major Player Table 9. Biotechnology and Pharmaceutical Companies Major Player Table 10. Immune Thrombocytopenia Drugs Industry Trends Table 11. Immune Thrombocytopenia Drugs Industry Drivers Table 12. Immune Thrombocytopenia Drugs Industry Opportunities and Challenges Table 13. Immune Thrombocytopenia Drugs Industry Restraints Table 14. Global Immune Thrombocytopenia Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Immune Thrombocytopenia Drugs Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Immune Thrombocytopenia Drugs Market Share by Region (2021-2026) Table 17. Global Immune Thrombocytopenia Drugs Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Immune Thrombocytopenia Drugs Market Share by Region (2027-2032) Table 19. Global Immune Thrombocytopenia Drugs Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Immune Thrombocytopenia Drugs Revenue Market Share by Players (2021-2026) Table 21. Global Immune Thrombocytopenia Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Immune Thrombocytopenia Drugs Key Players Headquarters & Area Served Table 23. Global Immune Thrombocytopenia Drugs Players, Product Type & Application Table 24. Global Immune Thrombocytopenia Drugs Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Immune Thrombocytopenia Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Immune Thrombocytopenia Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Immune Thrombocytopenia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Immune Thrombocytopenia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Immune Thrombocytopenia Drugs Revenue Market Share by Type (2021-2026) Table 31. Global Immune Thrombocytopenia Drugs Revenue Market Share by Type (2027-2032) Table 32. Global Immune Thrombocytopenia Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Immune Thrombocytopenia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Immune Thrombocytopenia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Immune Thrombocytopenia Drugs Revenue Market Share by Application (2021-2026) Table 36. Global Immune Thrombocytopenia Drugs Revenue Market Share by Application (2027-2032) Table 37. Novartis AG Company Information Table 38. Novartis AG Business Overview Table 39. Novartis AG Immune Thrombocytopenia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Novartis AG Immune Thrombocytopenia Drugs Product Portfolio Table 41. Novartis AG Recent Development Table 42. Merck & Co., Inc. Company Information Table 43. Merck & Co., Inc. Business Overview Table 44. Merck & Co., Inc. Immune Thrombocytopenia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Merck & Co., Inc. Immune Thrombocytopenia Drugs Product Portfolio Table 46. Merck & Co., Inc. Recent Development Table 47. Amgen Inc. Company Information Table 48. Amgen Inc. Business Overview Table 49. Amgen Inc. Immune Thrombocytopenia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Amgen Inc. Immune Thrombocytopenia Drugs Product Portfolio Table 51. Amgen Inc. Recent Development Table 52. Rigel Pharmaceuticals Inc. Company Information Table 53. Rigel Pharmaceuticals Inc. Business Overview Table 54. Rigel Pharmaceuticals Inc. Immune Thrombocytopenia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Rigel Pharmaceuticals Inc. Immune Thrombocytopenia Drugs Product Portfolio Table 56. Rigel Pharmaceuticals Inc. Recent Development Table 57. Horizon Therapeutics Plc Company Information Table 58. Horizon Therapeutics Plc Business Overview Table 59. Horizon Therapeutics Plc Immune Thrombocytopenia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Horizon Therapeutics Plc Immune Thrombocytopenia Drugs Product Portfolio Table 61. Horizon Therapeutics Plc Recent Development Table 62. CSL Ltd. Company Information Table 63. CSL Ltd. Business Overview Table 64. CSL Ltd. Immune Thrombocytopenia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. CSL Ltd. Immune Thrombocytopenia Drugs Product Portfolio Table 66. CSL Ltd. Recent Development Table 67. North America Immune Thrombocytopenia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 68. North America Immune Thrombocytopenia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 69. North America Immune Thrombocytopenia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 70. North America Immune Thrombocytopenia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 71. North America Immune Thrombocytopenia Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 72. North America Immune Thrombocytopenia Drugs Revenue by Country (2021-2026) & (US$ Million) Table 73. North America Immune Thrombocytopenia Drugs Revenue by Country (US$ Million) & (2027-2032) Table 74. Europe Immune Thrombocytopenia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 75. Europe Immune Thrombocytopenia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 76. Europe Immune Thrombocytopenia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 77. Europe Immune Thrombocytopenia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 78. Europe Immune Thrombocytopenia Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 79. Europe Immune Thrombocytopenia Drugs Revenue by Country (2021-2026) & (US$ Million) Table 80. Europe Immune Thrombocytopenia Drugs Revenue by Country (US$ Million) & (2027-2032) Table 81. China Immune Thrombocytopenia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 82. China Immune Thrombocytopenia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 83. China Immune Thrombocytopenia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 84. China Immune Thrombocytopenia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 85. Asia Immune Thrombocytopenia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 86. Asia Immune Thrombocytopenia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 87. Asia Immune Thrombocytopenia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 88. Asia Immune Thrombocytopenia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 89. Asia Immune Thrombocytopenia Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 90. Asia Immune Thrombocytopenia Drugs Revenue by Region (US$ Million) & (2021-2026) Table 91. Asia Immune Thrombocytopenia Drugs Revenue by Region (US$ Million) & (2027-2032) Table 92. SAMEA Immune Thrombocytopenia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 93. SAMEA Immune Thrombocytopenia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 94. SAMEA Immune Thrombocytopenia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 95. SAMEA Immune Thrombocytopenia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 96. SAMEA Immune Thrombocytopenia Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. SAMEA Immune Thrombocytopenia Drugs Revenue by Country (2021-2026) & (US$ Million) Table 98. SAMEA Immune Thrombocytopenia Drugs Revenue by Country (US$ Million) & (2027-2032) Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Immune Thrombocytopenia Drugs Image Figure 2. Global Immune Thrombocytopenia Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Immune Thrombocytopenia Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Intravenous Immunoglobins (IVIGs) Image Figure 5. Corticosteroids Image Figure 6. Thrombopoietin Receptor Agonists (TPO-RAs) Image Figure 7. Other Drugs Image Figure 8. Global Immune Thrombocytopenia Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Immune Thrombocytopenia Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospitals and Diagnostic Centers Image Figure 11. Academic Institutes and Research Organizations Image Figure 12. Biotechnology and Pharmaceutical Companies Image Figure 13. Global Immune Thrombocytopenia Drugs Market Size (US$ Million) & (2021-2032) Figure 14. Global Immune Thrombocytopenia Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Immune Thrombocytopenia Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Immune Thrombocytopenia Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Immune Thrombocytopenia Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Immune Thrombocytopenia Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Immune Thrombocytopenia Drugs Revenue Market Share by Type (2021-2032) Figure 21. Global Immune Thrombocytopenia Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Immune Thrombocytopenia Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Immune Thrombocytopenia Drugs Revenue Market Share by Application (2021-2032) Figure 24. North America Immune Thrombocytopenia Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Immune Thrombocytopenia Drugs Revenue Share by Type (2021-2032) Figure 26. North America Immune Thrombocytopenia Drugs Revenue Share by Application (2021-2032) Figure 27. North America Immune Thrombocytopenia Drugs Revenue Share by Country (2021-2032) Figure 28. United States Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Immune Thrombocytopenia Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Immune Thrombocytopenia Drugs Revenue Share by Type (2021-2032) Figure 33. Europe Immune Thrombocytopenia Drugs Revenue Share by Application (2021-2032) Figure 34. Europe Immune Thrombocytopenia Drugs Revenue Share by Country (2021-2032) Figure 35. Germany Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Immune Thrombocytopenia Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Immune Thrombocytopenia Drugs Revenue Share by Type (2021-2032) Figure 45. China Immune Thrombocytopenia Drugs Revenue Share by Application (2021-2032) Figure 46. Asia Immune Thrombocytopenia Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Immune Thrombocytopenia Drugs Revenue Share by Type (2021-2032) Figure 48. Asia Immune Thrombocytopenia Drugs Revenue Share by Application (2021-2032) Figure 49. Asia Immune Thrombocytopenia Drugs Revenue Share by Region (2021-2032) Figure 50. Japan Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Immune Thrombocytopenia Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Immune Thrombocytopenia Drugs Revenue Share by Type (2021-2032) Figure 58. SAMEA Immune Thrombocytopenia Drugs Revenue Share by Application (2021-2032) Figure 59. SAMEA Immune Thrombocytopenia Drugs Revenue Share by Country (2021-2032) Figure 60. Brazil Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Immune Thrombocytopenia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Intravenous Immunoglobins (IVIGs)
  • Corticosteroids
  • Thrombopoietin Receptor Agonists (TPO-RAs)
  • Other Drugs
Applications
  • Hospitals and Diagnostic Centers
  • Academic Institutes and Research Organizations
  • Biotechnology and Pharmaceutical Companies
Companies covered
  • Novartis AG
  • Merck & Co., Inc.
  • Amgen Inc.
  • Rigel Pharmaceuticals Inc.
  • Horizon Therapeutics Plc
  • CSL Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Immune Thrombocytopenia Drugs Market by Type
  3. 1.2.1 Global Immune Thrombocytopenia Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Intravenous Immunoglobins (IVIGs)
  5. 1.2.3 Corticosteroids
  6. 1.2.4 Thrombopoietin Receptor Agonists (TPO-RAs)
  7. 1.2.5 Other Drugs
  8. 1.3 Immune Thrombocytopenia Drugs Market by Application
  9. 1.3.1 Global Immune Thrombocytopenia Drugs Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospitals and Diagnostic Centers
  11. 1.3.3 Academic Institutes and Research Organizations
  12. 1.3.4 Biotechnology and Pharmaceutical Companies
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Immune Thrombocytopenia Drugs Market Dynamics
  1. 2.1 Immune Thrombocytopenia Drugs Industry Trends
  2. 2.2 Immune Thrombocytopenia Drugs Industry Drivers
  3. 2.3 Immune Thrombocytopenia Drugs Industry Opportunities and Challenges
  4. 2.4 Immune Thrombocytopenia Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Immune Thrombocytopenia Drugs Market Perspective (2021-2032)
  2. 3.2 Global Immune Thrombocytopenia Drugs Growth Trends by Region
  3. 3.2.1 Global Immune Thrombocytopenia Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Immune Thrombocytopenia Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Immune Thrombocytopenia Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Immune Thrombocytopenia Drugs Revenue by Players
  2. 4.1.1 Global Immune Thrombocytopenia Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Immune Thrombocytopenia Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Immune Thrombocytopenia Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Immune Thrombocytopenia Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Immune Thrombocytopenia Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Immune Thrombocytopenia Drugs Players, Product Type & Application
  8. 4.5 Global Immune Thrombocytopenia Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Immune Thrombocytopenia Drugs Market CR5 and HHI
  11. 4.6.3 2025 Immune Thrombocytopenia Drugs Tier 1, Tier 2, and Tier 3
5 Immune Thrombocytopenia Drugs Market Size by Type
  1. 5.1 Global Immune Thrombocytopenia Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Immune Thrombocytopenia Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Immune Thrombocytopenia Drugs Revenue Market Share by Type (2021-2032)
6 Immune Thrombocytopenia Drugs Market Size by Application
  1. 6.1 Global Immune Thrombocytopenia Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Immune Thrombocytopenia Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Immune Thrombocytopenia Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis AG
  2. 7.1.1 Novartis AG Company Information
  3. 7.1.2 Novartis AG Business Overview
  4. 7.1.3 Novartis AG Immune Thrombocytopenia Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis AG Immune Thrombocytopenia Drugs Product Portfolio
  6. 7.1.5 Novartis AG Recent Developments
  7. 7.2 Merck & Co., Inc.
  8. 7.2.1 Merck & Co., Inc. Company Information
  9. 7.2.2 Merck & Co., Inc. Business Overview
  10. 7.2.3 Merck & Co., Inc. Immune Thrombocytopenia Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck & Co., Inc. Immune Thrombocytopenia Drugs Product Portfolio
  12. 7.2.5 Merck & Co., Inc. Recent Developments
  13. 7.3 Amgen Inc.
  14. 7.3.1 Amgen Inc. Company Information
  15. 7.3.2 Amgen Inc. Business Overview
  16. 7.3.3 Amgen Inc. Immune Thrombocytopenia Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Amgen Inc. Immune Thrombocytopenia Drugs Product Portfolio
  18. 7.3.5 Amgen Inc. Recent Developments
  19. 7.4 Rigel Pharmaceuticals Inc.
  20. 7.4.1 Rigel Pharmaceuticals Inc. Company Information
  21. 7.4.2 Rigel Pharmaceuticals Inc. Business Overview
  22. 7.4.3 Rigel Pharmaceuticals Inc. Immune Thrombocytopenia Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Rigel Pharmaceuticals Inc. Immune Thrombocytopenia Drugs Product Portfolio
  24. 7.4.5 Rigel Pharmaceuticals Inc. Recent Developments
  25. 7.5 Horizon Therapeutics Plc
  26. 7.5.1 Horizon Therapeutics Plc Company Information
  27. 7.5.2 Horizon Therapeutics Plc Business Overview
  28. 7.5.3 Horizon Therapeutics Plc Immune Thrombocytopenia Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Horizon Therapeutics Plc Immune Thrombocytopenia Drugs Product Portfolio
  30. 7.5.5 Horizon Therapeutics Plc Recent Developments
  31. 7.6 CSL Ltd.
  32. 7.6.1 CSL Ltd. Company Information
  33. 7.6.2 CSL Ltd. Business Overview
  34. 7.6.3 CSL Ltd. Immune Thrombocytopenia Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 CSL Ltd. Immune Thrombocytopenia Drugs Product Portfolio
  36. 7.6.5 CSL Ltd. Recent Developments
8 North America
  1. 8.1 North America Immune Thrombocytopenia Drugs Revenue (2021-2032)
  2. 8.2 North America Immune Thrombocytopenia Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Immune Thrombocytopenia Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Immune Thrombocytopenia Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Immune Thrombocytopenia Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Immune Thrombocytopenia Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Immune Thrombocytopenia Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Immune Thrombocytopenia Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Immune Thrombocytopenia Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Immune Thrombocytopenia Drugs Revenue by Country
  11. 8.6.1 North America Immune Thrombocytopenia Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Immune Thrombocytopenia Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Immune Thrombocytopenia Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Immune Thrombocytopenia Drugs Revenue (2021-2032)
  2. 9.2 Europe Immune Thrombocytopenia Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Immune Thrombocytopenia Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Immune Thrombocytopenia Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Immune Thrombocytopenia Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Immune Thrombocytopenia Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Immune Thrombocytopenia Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Immune Thrombocytopenia Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Immune Thrombocytopenia Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Immune Thrombocytopenia Drugs Revenue by Country
  11. 9.6.1 Europe Immune Thrombocytopenia Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Immune Thrombocytopenia Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Immune Thrombocytopenia Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Immune Thrombocytopenia Drugs Revenue (2021-2032)
  2. 10.2 China Immune Thrombocytopenia Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Immune Thrombocytopenia Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Immune Thrombocytopenia Drugs Revenue by Type (2027-2032)
  5. 10.3 China Immune Thrombocytopenia Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Immune Thrombocytopenia Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Immune Thrombocytopenia Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Immune Thrombocytopenia Drugs Revenue by Application (2027-2032)
  9. 10.5 China Immune Thrombocytopenia Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Immune Thrombocytopenia Drugs Revenue (2021-2032)
  2. 11.2 Asia Immune Thrombocytopenia Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Immune Thrombocytopenia Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Immune Thrombocytopenia Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Immune Thrombocytopenia Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Immune Thrombocytopenia Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Immune Thrombocytopenia Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Immune Thrombocytopenia Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Immune Thrombocytopenia Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Immune Thrombocytopenia Drugs Revenue by Country
  11. 11.6.1 Asia Immune Thrombocytopenia Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Immune Thrombocytopenia Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Immune Thrombocytopenia Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Immune Thrombocytopenia Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Immune Thrombocytopenia Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Immune Thrombocytopenia Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Immune Thrombocytopenia Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Immune Thrombocytopenia Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Immune Thrombocytopenia Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Immune Thrombocytopenia Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Immune Thrombocytopenia Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Immune Thrombocytopenia Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Immune Thrombocytopenia Drugs Revenue by Country
  11. 12.6.1 SAMEA Immune Thrombocytopenia Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Immune Thrombocytopenia Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Immune Thrombocytopenia Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst